[Immunotherapy Based on Tumor Microenvironment in Renal Cell Carcinoma]

Area of Science:

• Uro-oncology
• Cancer immunology
• Translational oncology

Background:

• Renal cell carcinoma (RCC) is a lethal urological cancer where distant metastasis is the primary cause of death.
• Targeted agents have improved prognosis, but therapeutic resistance remains a significant challenge for RCC patients.
• Immune checkpoint inhibitors and immunotherapy targeting the tumor microenvironment (TME) offer new clinical applications for advanced RCC.

Purpose of the Study:

• To review the characteristics of the tumor microenvironment (TME) in renal cell carcinoma (RCC).
• To identify candidate predictive biomarkers for therapeutic response in RCC.
• To explore potential targets for future drug development in advanced RCC.

Main Methods:

• Literature review of studies on renal cell carcinoma (RCC) and tumor microenvironment (TME).
• Analysis of current targeted therapy and immunotherapy strategies for RCC.
• Synthesis of information on biomarkers and potential therapeutic targets.

Main Results:

• The tumor microenvironment (TME) plays a critical role in the progression and treatment response of RCC.
• Combination strategies involving targeted therapy and immunotherapy show promising results for advanced RCC.
• Understanding TME characteristics is crucial for developing effective predictive biomarkers and novel therapeutic targets.

Conclusions:

• The combination of targeted therapy and immunotherapy represents a promising future direction for managing advanced renal cell carcinoma (RCC).
• Further research into TME characteristics, biomarkers, and novel drug targets is essential for improving patient outcomes in RCC.
• Personalized therapeutic approaches based on TME insights may overcome treatment resistance in RCC.